March 16, 2022
1 min watch
Save
VIDEO: Phase 3 studies completed for presbyopia drop
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW ORLEANS – Orasis Pharmaceuticals has completed two phase 3 studies of its presbyopia candidate, CSF-1, CEO Elad Kedar said here at SECO 2022.
The company will share the topline results from the NEAR-1 and NEAR-2 studies soon, he said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Kedar reports he is CEO of Orasis Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.